Statement of Principles concerning malignant neoplasm of the ovary (Reasonable Hypothesis) (No. 9 of 2018)

The instrument operationalises the "reasonable hypothesis" standard for causation between disease (malignant neoplasm of the ovary) and relevant service by converting epidemiological and clinical associations into discrete, administrable factors with quantitative and temporal thresholds. The Repatriation Medical Authority states that it has a view that "sound medical‑scientific evidence" supports the proposition that ovarian malignant neoplasms can be related to relevant service (s 8). That statement is the Authority’s declaratory basis for setting the list of factors in s 9.

Core legal and technical concepts embedded in the instrument are:

• Reasonable hypothesis as a threshold evidentiary concept. The Statement says that at least one enumerated factor must exist "before it can be said that a reasonable hypothesis has been raised" connecting the disease with service (s 9 introductory text). The instrument does not itself define the broader legal meaning of "reasonable hypothesis", but it makes the listed factors the minimum prerequisites for that standard in the context of ovarian cancer claims under the VEA/MRCA framework.
• Relevant service. The causal connection required is specified as relationship to "relevant service", which is given a specific list of service types in the Schedule (including operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA). The instrument therefore requires not only a medical/behavioural factor but an evidentiary linkage to service as defined (Schedule 1: "relevant service"; s 10(1)).
• Quantitative and temporal thresholds. The Statement translates epidemiological associations into concrete thresholds,examples include a cumulative equivalent radiation dose of 0.1 sievert and a latency period of at least five years (s 9(2)); asbestos exposure measured in cumulative work hours with different thresholds for enclosed versus open environments and latency of at least five years (s 9(4)-(5)); obesity defined by BMI ≥ 30 sustained for defined durations (s 9(3) and Schedule 1); talc use quantified as "on more days than not" for five years (s 9(9)); and smoking quantified as at least five pack‑years with commencement and cessation timing conditions for mucinous tumours (s 9(11)).
• Condition subtyping. Certain factors are restricted to histological subtypes: s 9(10) applies only to epithelial ovarian cancer; s 9(11) applies only to mucinous ovarian tumours. The Statement therefore requires tumour classification for some factors to be applicable.
• Use of external technical standards. The Schedule requires calculation of "cumulative equivalent dose" in accordance with the ARPANSA Guide (Schedule 1: cumulative equivalent dose), thereby importing an external technical methodology to standardise dose reconstruction.

Mechanically, the Statement prioritises administrability: it sets discrete factors that, if satisfied and linked to relevant service, are declared sufficient to raise the reasonable hypothesis. This converts a range of clinical and exposure histories into a checklist that decision‑makers can apply, subject to the definitions and methodological rules in the Schedule.

From a decision‑process perspective, the instrument shifts the evidentiary task for claimants: they must show at least one enumerated factor in s 9 (measured as directed in Schedule 1) and demonstrate its relation to relevant service (s 10(1)). The Statement also controls the scope of reliance on other Statements of Principles by instructing that, where a factor refers to another injury or disease covered by another Statement, the factors in that other Statement apply "in accordance with the terms of that Statement" (s 11).

Primary groups affected are claimants (veterans and former members of the Forces) and decision‑makers handling claims under the VEA and MRCA. The instrument applies specifically to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). "Relevant service", as defined in the Schedule, encompasses operational service, peacekeeping, hazardous service, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA. Therefore persons who rendered any of those classes of service and who develop ovarian malignant neoplasm (or die from it) are within the instrument’s ambit.

The instrument differentiates within the affected claimant population by biological status and tumour type:

• Parous women. One factor (s 9(6)) refers only to "parous women" and requires evidence of inability to breastfeed for a cumulative six months. The Schedule notes that cumulative breastfeeding can be across multiple pregnancies.
• Tumour subtypes. Factors are subtype‑specific: s 9(10) applies only to epithelial ovarian cancer (relevant to those with that histology); s 9(11) applies only to mucinous ovarian tumours and requires quantified tobacco exposure.
• Claimants who were treated or had events before, during or after service. Factor 12 (s 9(12)), inability to obtain appropriate clinical management, is limited by s 10(2): it applies only to material contribution or aggravation where the malignant neoplasm was suffered or contracted before or during (but did not arise out of) service. That narrows the set of claimants who can rely on factor 12.

Other affected actors include administrative and medical assessors who must apply the Statement: the Repatriation Medical Authority has prescribed measurement rules in Schedule 1 (for example BMI calculation, MET units, pack‑year calculation, and ARPANSA methodology for dose reconstruction). Decision‑makers must use those definitions (Schedule 1) when determining whether an enumerated factor exists.

Service providers and record‑holders are indirectly affected because claimants will need records to satisfy the thresholds: medical records showing endometriosis diagnosis and duration (s 9(1)); occupational records or contemporaneous logs to evidence asbestos exposure hours and task types (s 9(4)-(5)); radiation exposure records and dose reconstruction to establish cumulative equivalent dose to the ovary (s 9(2) and Schedule); pharmacy or prescribing records for hormone replacement therapy histories (s 9(10)(b)); and smoking histories documented in medical notes or occupational health records for pack‑years (s 9(11) and Schedule).

Finally, because the Statement links to other Statements (s 11), decision‑makers and claimants involved in overlapping conditions will be affected by the content and measurement rules of those other Statements of Principles as they apply in a given case.

This instrument is not a statute that imposes criminal or civil duties directly on private individuals. It is a statutory medical standard used to determine whether a "reasonable hypothesis" has been raised that ovarian malignant neoplasm (or death from it) is related to relevant service. The operative duties and rights are best understood in the administrative context in which the Statement operates.

Rights and evidentiary consequences:

• Claimants have the right to have the Statement applied to their claim under the VEA/MRCA scheme. The Statement defines the minimum factors that must exist to say that a reasonable hypothesis has been raised (s 9). Thus, claimants who can show that at least one enumerated factor exists and that it relates to their relevant service (s 10(1)) are, by operation of the Statement, positioned to meet the "reasonable hypothesis" threshold as a matter of the Scheme’s evidentiary architecture.
• Where a factor in s 9 refers to an injury or disease covered by another Statement of Principles, the claimant can rely on the factors in that other Statement "in accordance with the terms of that Statement" (s 11). This creates a right to import the terms and measurement rules of other Statements where the factor invokes them.

Duties and decision‑maker obligations:

• Decision‑makers charged with adjudicating claims must apply this Statement when determining whether the reasonable hypothesis is established, by checking whether at least one of the s 9 factors exists and whether it is related to relevant service (s 9 and s 10). The instrument provides measurement definitions and external methodological references (Schedule 1) that frame how decision‑makers must assess factors such as cumulative radiation dose, BMI, METs, and pack‑years.
• The instrument revokes the earlier SOP (No. 70 of 2009) (s 4), which creates an administrative duty to apply this Statement instead of the revoked version for claims within its application period (s 5).

Limitations and conditional rights:

• Factor 12 (inability to obtain appropriate clinical management) is delimited by s 10(2). It applies only to "material contribution to, or aggravation of, malignant neoplasm of the ovary where the person's malignant neoplasm... was suffered or contracted before or during (but did not arise out of) the person's relevant service" (s 10(2)). That means the right to rely on factor 12 is conditional on the disease timeline relative to service.
• Tumour subtype specificity constrains reliance on some factors: s 9(10) applies only to epithelial ovarian cancer and s 9(11) only to mucinous tumours. The claimant therefore bears the burden of producing histopathology or other evidence of tumour subtype to invoke those factors.

Measurement and proof duties derive from the Schedule. For radiation exposure, decision‑makers must use the ARPANSA Guide methodology referenced in Schedule 1 for cumulative equivalent dose calculation. For BMI, the Schedule prescribes the BMI formula (W/H2). For smoking, the Schedule prescribes the pack‑year calculation and conversions for different tobacco products. These definitional duties set how the factual proof must be presented and evaluated.

The instrument itself does not create procedural rights such as disclosure timings or appeal mechanisms; those procedural matters are governed by the VEA/MRCA and administrative processes to which the Statement applies. The Statement shapes the substantive evidentiary minimum required to establish a reasonable hypothesis, thereby creating practical rights and obligations in claims processing.

The Statement of Principles is an administrative medical instrument rather than a penal statute. The instrument does not prescribe criminal penalties, fines or civil sanctions in its text. There are no penalty provisions in the Statement itself. Instead, the Statement functions as a statutory medical standard to be applied by decision‑makers under the VEA and MRCA claim frameworks (see s 3 and s 5). Enforcement therefore operates via administrative adjudication of entitlement claims rather than by penal sanction.

Mechanisms through which the Statement will be enforced in practice include:

• Application in claims under sections of the VEA/MRCA. The Statement applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). Those provisions in the parent Acts set the administrative scheme under which entitlement decisions are made. Decision‑makers administering the Acts will use this Statement to determine whether the "reasonable hypothesis" threshold is met.
• Revocation of the prior Statement. By revoking the earlier Statement No. 70 of 2009 (s 4), the instrument changes the medical standard decision‑makers must apply. The practical consequence is that decisions from the date of commencement must be informed by this Statement rather than the revoked instrument.

The Statement instructs assessors on how to quantify exposures and conditions (Schedule 1). Decision‑makers are therefore expected to employ the specified methods,e.g. ARPANSA Guide for cumulative equivalent dose, BMI calculation, pack‑year calculations,when reconstructing exposures or assessing physiological metrics. Non‑compliance with the methodology by decision‑makers would be an administrative error subject to the review and appeal mechanisms provided under the VEA/MRCA and general administrative law, although such procedural remedies are outside the instrument itself.

Because the Statement interacts with other Statements of Principles (s 11), there may be administrative enforcement in the sense that decision‑makers must apply other Statements where a s 9 factor refers to an injury or disease covered by another Statement; those other Statements may impose additional methodological or threshold requirements.

In short, the instrument does not impose criminal penalties. Enforcement is through the administrative apparatus that applies the VEA/MRCA; the Statement prescribes the medical criteria and measurement methods that must be applied when deciding claims. Any consequences for incorrect application will flow from the remedial and review provisions of the VEA/MRCA and administrative law, not from the Statement itself.

This Statement is a statutory instrument made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3). Its legal effect and application are therefore set within the VEA/MRCA entitlement framework: it applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). Those parent Acts provide the statutory claims framework that gives effect to the Statement; the Statement itself supplies the medical criteria for establishing the "reasonable hypothesis" within that framework.

Key cross‑references and interactions explicitly set out in the instrument include:

• Integration with other Statements of Principles. Section 11 provides that where a factor in this Statement refers to an injury or disease that is covered by another Statement of Principles, the factors in that other Statement apply "in accordance with the terms of that Statement as in force from time to time." This creates a cross‑instrument dependency: evaluating a s 9 factor may require recourse to another Statement for measurement rules or additional prerequisites.
• Technical standards external to the VEA. Schedule 1 requires that "cumulative equivalent dose" be calculated in accordance with the ARPANSA Guide: "Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017" (Schedule 1: cumulative equivalent dose). That imports a technical methodology produced by ARPANSA into the legal assessment process.
• ICD‑10‑AM coding. Section 7(3)-(4) notes that while the condition commonly attracts ICD‑10‑AM codes C56 or D39.1, the definition in s 7(2) controls. Nevertheless, the instrument expressly anchors diagnostic classification to the ICD‑10‑AM Tenth Edition (effective 1 July 2017) for cross‑referencing purposes.
• Revocation of earlier instrument. Section 4 revokes the earlier Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009. Administrative decisions and claims made after commencement are to be assessed against this instrument rather than the revoked instrument.
• Parent Acts and administrative procedure. The Statement operates only in the context of the VEA and MRCA schemes. Procedural matters,such as how claims are lodged, review rights, time limits and payments,remain governed by the parent Acts and their regulations. The Statement provides the medical causation criteria within that larger statutory and administrative apparatus.

The Statement does not, on its face, amend the VEA or MRCA nor does it create private rights of action outside the entitlements framework. Its interaction with other laws is primarily to supply the medical standard for entitlement decisions, to incorporate external scientific guidance where specified, and to cross‑apply other Statements of Principles when the factors invoke other conditions. Where other statutory provisions require a "reasonable hypothesis", this Statement defines what will, in practice, satisfy that threshold for ovarian malignant neoplasm claims covered by the identified sections of the VEA and MRCA.

The compiled text includes amendments up to Amendment Statement of Principles concerning malignant neoplasm of the ovary (Reasonable Hypothesis) (No. 35 of 2018), with a compilation date of 2 April 2018 (compilation header). The instrument was made by the Repatriation Medical Authority and dated 22 December 2017 (instrument body). The legislation history in the endnotes records the following chronology (Endnote 3):

• Statement of Principles concerning malignant neoplasm of the ovary (Reasonable Hypothesis) (No. 9 of 2018) was registered 2 January 2018 (F2018L00010) and commenced 29 January 2018.
• Amendment Statement of Principles concerning malignant neoplasm of the ovary (Reasonable Hypothesis) (No. 35 of 2018) was registered 5 March 2018 (F2018L00185) and its day of commencement is 2 April 2018. The compilation includes amendments up to that instrument (compilation preamble).

Endnote 4 (Amendment history) specifies that subsection 10(2) was repealed and substituted (rs) by Instrument No. 35 of 2018. The Main text shows subsection 10(2) as it stands in the compilation, and the endnotes indicate that the text was affected by the amendment. The instrument also expressly revokes the earlier Statement No. 70 of 2009 (s 4), so the 2018 instrument replaced the 2009 Statement for relevant claims.

Additional points from the compilation notes:

• The compilation states it shows the text as amended and in force on 2 April 2018, and that uncommenced amendments are not shown in the text of the compiled law (compilation header). Readers are notified that any uncommenced amendments are accessible on the Legislation Register.
• The Schedule defines technical terms and references the ARPANSA Guide "as in force on 2 August 2017", thereby fixing the edition of that external technical guidance that is to be used for dose reconstruction at the date specified.

For practitioners, the amendment history means that decision‑makers and advisers must apply the No. 9 of 2018 Statement as amended by No. 35 of 2018 from its commencement date. Historical claims decided under the revoked 2009 Statement may be distinguishable from those decided under the 2018 Statement. The endnotes and amendment history should be consulted to confirm which version applied at any particular decision date.

The instrument and the compilation provided do not record any judicial decisions, litigation outcomes, or case law that directly interpret or apply this specific Statement of Principles. The text contains no citations to cases and the endnotes do not record any litigation history. The instrument is an administrative medical determination by the Repatriation Medical Authority and, as compiled, is presented without judicial annotation.

Practitioners seeking litigation history or judicial interpretation will need to consult external case reports and administrative tribunal decisions relevant to the VEA/MRCA and Statements of Principles more broadly. The Statement itself does not record such material or list decided cases. Where factors refer to other Statements (s 11), litigation concerning those other Statements might be relevant; that possibility is not reflected in the instrument and must be established from external sources.

Because the Statement imports technical methodologies (for example the ARPANSA Guide for cumulative equivalent dose), disputes in litigation may involve expert evidence about how those methodologies are applied to an individual’s exposure history. The instrument does not provide guidance on how tribunals have handled such evidentiary disputes; to locate litigation history affecting interpretation or application of the measurement rules or thresholds, advisers must search tribunal and court decisions relating to the VEA/MRCA and Statements of Principles generally.

In short, no litigation history is included in the instrument as compiled. Any judicial or tribunal interpretation would be external to this text and must be sought through case law research.

The Statement contains multiple potential pitfalls for claimants, advisers and decision‑makers because it converts broad epidemiological associations into tightly specified, measurable factors and temporal windows. Key practical "gotchas" grounded in the instrument’s text are:

• Necessity of at least one enumerated factor. The Statement makes clear that "at least one of the following factors must as a minimum exist" before a reasonable hypothesis can be said to be raised (s 9 introductory text). Absent an enumerated factor established under the Statement’s definitions and measurement rules, a claimant cannot rely on this Statement to establish the reasonable hypothesis threshold. Informal or general arguments about exposure or susceptibility that do not map to a listed factor will not suffice under this Statement.
• Temporal windows and latency requirements. Many factors include explicit time limits or latency periods. Examples: radiation requires the first exposure to be at least five years before clinical onset (s 9(2)); asbestos requires first inhalation at least five years before onset (s 9(4)-(5)); obesity must persist "for at least five years within the 20 years before the clinical onset" (s 9(3)); physical inactivity requires inability "for at least ten years within the 30 years before clinical onset" (s 9(7)); vegetable consumption shortfall requires five consecutive years within the prior 20 years (s 9(8)). These windows create evidentiary burden for claimants to document when exposures or conditions occurred relative to clinical onset.
• Measurement specificity. The Schedule prescribes how several key metrics are calculated: BMI (Schedule 1: BMI), cumulative equivalent dose (Schedule 1 referencing ARPANSA Guide), MET units (Schedule 1), and pack‑year calculations for smoking (Schedule 1). Failure to present evidence in the form required, or failure to use the ARPANSA Guide for dose reconstruction, risks rejection of the factor on methodological grounds.
• Asbestos exposure thresholds and task specificity. Asbestos factors set different cumulative hours for enclosed (1 000 hours) and open (3 000 hours) environments and require exposure to occur "at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled" (s 9(4)-(5)). Establishing these task‑specific exposures and counting cumulative hours can be challenging, particularly for historical exposures lacking detailed records.
• Talc factor phrasing. The talc factor (s 9(9)) requires talc to be applied to the perineal area "on more days than not, for a period of at least five years". The phrase "on more days than not" introduces an aggregate frequency threshold that may be hard to document without contemporaneous habit evidence or reliable witness statements.
• Subtype dependence. Several factors apply only to specific histological subtypes (s 9(10) for epithelial cancers; s 9(11) for mucinous tumours). If histology is ambiguous or unavailable, reliance on those factors may be precluded. Claimants must obtain histopathology reports to determine applicability.
• Factor 12 limitation. The inability to obtain appropriate clinical management factor is limited by s 10(2): it applies only where the malignant neoplasm was "suffered or contracted before or during (but did not arise out of) the person's relevant service" and only to material contribution or aggravation. This temporal and causal restriction narrows the circumstances in which this factor can support a claim.
• Smoking calculation complexity. The Schedule defines pack‑years and equivalences to different tobacco products using weight conversions (Schedule 1). For claimants whose tobacco use includes combinations of products, accurate conversion and historical quantification are required to reach the five pack‑year threshold in s 9(11).
• Dietary and activity evidence burdens. Factors such as inability to consume at least 150 grams/day of vegetables for five consecutive years (s 9(8)) and inability to undertake physical activity >3 METs for ten years (s 9(7)) require longitudinal lifestyle evidence. Medical records rarely contain continuous dietary logs or precise physical activity MET‑based assessments over long periods, making these thresholds difficult to establish without supplementary evidence.
• Radiation dose reconstruction requirements. The cumulative equivalent dose threshold is modest (0.1 Sv), but the Schedule requires dose calculation using the ARPANSA Guide "as in force on 2 August 2017." Dose reconstruction for specific organs (ovary) requires combining external and internal exposures averaged over organ mass. If service records or monitoring data are incomplete, reconstructing a 0.1 Sv cumulative dose to the ovary may be technically complex and reliant on expert reconstruction using the prescribed methodology.
• Interaction with other Statements. Where a s 9 factor refers to another condition covered by another Statement, assessors must apply that Statement "as in force from time to time" (s 11). This can complicate proof when multiple Statements interlock or when other Statements have differing measurement rules.
• ICD code versus statutory definition. Section 7(3) makes clear that, although ICD‑10‑AM codes are relevant, the statutory meaning is the definition in s 7(2). Practitioners must ensure that the clinical diagnosis aligns with the instrument's definition rather than relying solely on ICD coding.

Each of these matters creates potential evidentiary and procedural traps. Practitioners should plan evidence collection and expert input to match the precise measurement and temporal formulations in the Statement and the Schedule.

For claimants and advisers seeking to use this Statement in a claim under the VEA or MRCA, compliance means assembling documentary and expert evidence that maps to the Statement’s enumerated factors and to the Schedule’s measurement rules, and demonstrating the relationship of the proven factor to the person's relevant service as defined in the Schedule.

Practical steps, grounded in the text:

1. Identify the clinical onset date and tumour subtype

   • Obtain clinical records to establish the date of clinical onset of the ovarian malignant neoplasm and histopathology to classify tumour subtype (epithelial, mucinous, etc.), because some factors (s 9(10), s 9(11)) apply only to specific histologies. Section 7(5) also requires inclusion of death from a terminal event that was contributed to by the malignant neoplasm, so death certificates and terminal event documentation may be needed for deceased claimants.

2. Map potential factors to the timeline

   • For each factor in s 9 that may apply, verify the temporal requirements relative to clinical onset (for instance, five‑year latency for radiation and asbestos first inhalation, five‑year cumulative periods for obesity or talc use, ten‑year windows for HRT cessation etc.). The Statement repeatedly conditions factors on timing (s 9). Prepare a timeline that shows exposures, diagnoses, pregnancies, breastfeeding periods and any cessation dates for smoking or HRT.

3. Compile objective medical records and expert assessments

   • Endometriosis (s 9(1)): gather gynaecology records specifying diagnosis date(s) and evidence of at least five years’ duration before clinical onset.
   • Obesity (s 9(3) and Schedule): compile weight/height records across the relevant 20‑year window and calculate BMI using Schedule 1 formula (W/H2) to show BMI ≥ 30 for at least five years within the 20 years before onset.
   • Physical inactivity (s 9(7) and Schedule): secure clinical assessments that document functional capacity, mobility, and exercise tolerance, and where necessary obtain occupational medical assessments that quantify MET limitations (Schedule 1 defines MET) over the relevant ten‑year within‑30‑year period.
   • Dietary shortfall (s 9(8)): assemble medical, dietetic or other records, and witness statements if needed, that support inability to consume an average of at least 150 g/day of vegetables for five consecutive years within the 20 years before onset.
   • Talc use (s 9(9)): obtain personal statements, family statements, consumer purchase or product usage evidence indicating perineal talc application "on more days than not" for five years.
   • Breastfeeding (s 9(6)): for parous claimants, produce obstetric records documenting breastfeeding duration across pregnancies; the Statement explicitly allows cumulative breastfeeding across multiple pregnancies.
   • HRT (s 9(10)(b)): obtain prescribing records, pharmacy dispensing history and specialist notes showing at least five consecutive years of hormone replacement therapy and any cessation dates to test the ten‑year post‑cessation window.
   • Smoking history (s 9(11) and Schedule): collect smoking history, including number of cigarettes per day and years of use, convert to pack‑years per Schedule 1 (one pack‑year = 20 tailor‑made cigarettes/day for one year) and show commencement at least ten years before onset and cessation timing relative to the 30‑year window if cessation applies.
   • Asbestos exposure (s 9(4)-(5)): retrieve employment records, rosters, task descriptions and contemporaneous safety reports showing cumulative hours in enclosed or open environments and that exposure occurred during tasks involving application, removal, dislodgement, cutting or drilling of asbestos‑containing material. Where records are incomplete, consider affidavits from co‑workers and expert occupational hygiene reconstruction; be aware the Statement requires cumulative hour thresholds (1 000 hours enclosed; 3 000 hours open) and first exposure at least five years before onset.
   • Radiation dose (s 9(2) and Schedule): assemble radiation badge records, medical imaging and therapy records, flight logs for aircrew, and military radiation monitoring when available. Commission dose reconstruction using the ARPANSA Guide referenced in Schedule 1 to calculate cumulative equivalent dose to the ovary, ensuring the methodology conforms to the Guide "as in force on 2 August 2017". The threshold is at least 0.1 sievert and at least five years before clinical onset.
   • Inability to obtain appropriate clinical management (s 9(12) and s 10(2)): document attempts to obtain care, evidence of service limitations, refusal or inability to access appropriate diagnostics or treatment, and show this occurred before or during service for cases where the disease was suffered or contracted before/during service but did not arise out of service. This factor has explicit temporal and causal constraints under s 10(2).

4. Establish linkage to relevant service

   • For any factor established, gather service records that corroborate the factor’s relation to "relevant service" (see Schedule 1: relevant service list). For asbestos or radiation exposures potentially occurring in service, produce service unit logs, deployment records, position descriptions and any occupational health surveillance records linking the exposure to the period/role of relevant service. Section 10(1) requires the factor to be related to relevant service.

5. Use the Schedule’s measurement rules

   • Ensure all quantitative calculations follow Schedule 1: BMI formula, MET units, pack‑year definitions and ARPANSA Guide methodology for cumulative equivalent dose. Decision‑makers will apply these prescribed methods when assessing whether threshold values have been met.

6. Cross‑reference other Statements where applicable

   • If a s 9 factor refers to another injury or disease that has its own Statement of Principles, consult that Statement and prepare evidence that meets its terms (s 11). For example, if a factor depends on a separate diagnosis governed by another Statement, assemble evidence required by that other Statement.

7. Prepare admissible expert evidence

   • When required by complex reconstructions (e.g. organ dose estimation under ARPANSA methods, occupational exposure reconstruction or MET quantification), obtain expert reports that explicitly address the Statement’s thresholds and cite the Schedule’s methodology. Experts should translate historical records into the quantitative formats the Statement requires.

8. Anticipate evidentiary gaps and address them proactively

   • Where contemporary monitoring is absent (common for older service), prepare sworn statements, contemporaneous documentary evidence and expert reconstructions. For dietary and activity factors, consider corroborative family or employer statements and clinical assessments. For talc use and smoking history, contemporaneous consumer or medical records enhance credibility.

9. Note the Statement’s scope and plan appeals accordingly

   • The Statement sets the minimum that must exist to raise a reasonable hypothesis (s 9). If a claimant cannot meet those minima under the Statement, they should consider whether other legal routes or different Statements of Principles may apply. Procedural steps for review or appeal are governed by the VEA/MRCA and administrative law.

10. Document the decision chain

• Save all primary source documents, expert reports and calculations that follow the Schedule, because decision‑makers will evaluate the existence and relation of a factor using those materials. Where another Statement is invoked (s 11), keep a clear trail showing how evidence maps onto both Statements.

Following the instrument strictly means matching evidence to the textual and definitional requirements in s 9 and Schedule 1 and demonstrating the relationship to relevant service under s 10. The Statement is explicit about measurement and temporal requirements; compliance requires assembling evidence that meets those exacting prescriptions rather than relying on general clinical statements or unquantified assertions.